Oxytocin vs Pancragen
Side-by-side comparison of key properties, dosing, and research.
- Summary
- Oxytocin is a 9-amino acid neuropeptide produced in the hypothalamus with diverse roles in social bonding, trust, stress reduction, and sexual function. Exogenous administration is used therapeutically to improve social cognition, reduce anxiety, and enhance intimacy.
- Pancragen is a tripeptide bioregulator (Lys-Glu-Asp) developed by Professor Vladimir Khavinson, tissue-specific for the pancreas. It supports the function of both exocrine and endocrine pancreatic cells, promotes normalization of insulin secretion from beta cells, and may offer protective effects against pancreatic aging and diabetic progression.
- Half-Life
- ~3–5 minutes (IV); ~30–60 minutes (intranasal, CNS effects persist longer)
- Short (minutes); sustained gene-regulatory effects
- Admin Route
- Intranasal, SubQ, IV
- SubQ, Oral
- Research
- —
- —
- Typical Dose
- 20–40 IU
- 10 mg per day
- Frequency
- As needed (not daily long-term)
- Daily for 10–30 days
- Key Benefits
- Enhances social bonding and trust
- Reduces social anxiety and fear of rejection
- Improves autism spectrum symptoms (social cognition)
- Reduces cortisol and stress reactivity
- Enhances sexual arousal and intimacy
- Promotes maternal behavior and bonding
- May improve depressive symptoms
- Appetite suppression and metabolic effects
- Supports pancreatic beta cell function and insulin secretion
- May improve glucose metabolism in early metabolic dysfunction
- Protective effects on exocrine pancreatic tissue
- Anti-aging effects on pancreatic cells
- Potential support in type 2 diabetes management alongside standard care
- Reduces pancreatic cellular apoptosis from metabolic stress
- Complementary to GLP-1 agonists in metabolic protocols
- Side Effects
- Mild uterine cramping (avoid in pregnancy)
- Nasal irritation (intranasal)
- Headache
- Potential emotional over-attachment or jealousy amplification
- +2 more
- Generally well tolerated
- Mild injection site reactions
- No significant hypoglycemic events reported at standard doses as monotherapy
- Stacks With
- —
- —